Eisai Co., Ltd.

Supporting brain health starts in the community. Eisai is pleased to launch a new collaboration with Lawson and Wellness Dining in Imabari City, Japan, focused on helping people learn about cognitive health and take proactive steps toward reducing the risk of cognitive decline. By bringing education, self-assessment, and nutrition support into familiar everyday settings, we're working to make brain health more accessible and actionable for everyone. This initiative reflects our commitment to building a dementia ecosystem through cross-sector collaboration and advancing a more inclusive society.

Knowledge exchange across continents🌊 We were excited to welcome five researchers from Liverpool School of Tropical Medicine and the University of Liverpool to our Tsukuba Research Laboratories. As partners dedicated to advancing drug discovery for patients affected by infectious diseases, we held thoughtful and productive discussions, opening up promising perspectives on future collaboration.

海を越えた知の交流🌊 Liverpool School of Tropical MedicineおよびUniversity of Liverpoolの研究者5名が筑波研究所を訪問しました。 感染症領域で患者様のための創薬に取り組む仲間として、刺激的で実りある議論が交わされました。 コラボレーションの可能性についても意見が交わされ、新たなアイデアが生まれる機会となりました。

Expanding the possibilities of global health. ✨ We recently welcomed Dr. Nick Cammack from the Wellcome Trust to our Tsukuba Research Laboratories. The Wellcome Trust is a UK-based global charitable foundation that supports discovery research into life, health and wellbeing.  Exchanging insightful perspectives on future efforts, this visit strengthened our shared commitment to supporting those affected by infectious diseases.

広がる、グローバルヘルスの可能性✨ Wellcome Trust のNicholas Cammack博士が筑波研究所を訪問しました。 Wellcome Trustは英国に拠点を置き、生命・健康・ウェルビーイングに関する研究を支援するグローバルな研究助成財団です。Cammack博士と今後のグローバルヘルス領域における取り組みに向け、有意義な意見交換が行われました。感染症などで困難に直面する人々の助けになりたいという共通の想いを確認しました。

Employees at Eisai’s Tsukuba Research Laboratories recently came together for a quiz competition and a little friendly rivalry. The quiz featured a mix of Eisai-related questions and challenging research trivia, putting participants’ knowledge and expertise to the test. In an exciting matchup between the veteran team led by the Director of the Research Laboratories and a team of younger employees, the younger team took the win! 👑 The event wrapped up with a social gathering, giving colleagues from different departments and generations a chance to connect, share experiences, and enjoy time together outside of their day-to-day work. These connections help create an environment where collaboration thrives and research moves forward together.

Eisai traces its origins to Nihon Eisai Co., Ltd. (日本衛材株式会社), established in 1941. The name Nihon Eisai combines 日本 (Nihon), meaning “Japan,” and 衛材 (Eisai), meaning “sanitary or healthcare supplies.” Later, in 1955, founder Toyoji Naito changed our name to Eisai Co., Ltd. (エーザイ), written in katakana, a rather unusual choice at the time. One reason was that Nihon Eisai Co., Ltd. was long and cumbersome to write. Another was that many companies in those days began with “Nihon” (日本, “Japan”), making them difficult to distinguish and harder to find in the telephone directory. Today, company names written in katakana are commonplace, but in the 1950s they were still relatively rare. We like to think that our innovative spirit and willingness to embrace new ideas were already reflected in this bold decision to adopt a katakana company name!

Did you know? Before Eisai became a global pharmaceutical company, its origins trace back to the Sakuragaoka Laboratory, founded by Toyoji Naito in 1936. Just two years later, the laboratory introduced Japan's first commercial vitamin E product, developed from wheat germ oil extract. From a small research laboratory to a global organization, innovation and a commitment to improving people's lives have been part of Eisai's story from the beginning.

Innovation begins with dialogue. Dr. Koen Dechering and Dr. Walter Bronkhorst from TropIQ Health Sciences visited our Tsukuba Research Laboratories. TropIQ is a Dutch company providing a state-of-the-art technology platform for accelerated discovery and development of interventions to combat vector-borne diseases. Together, as collaborators in antimalarial R&D, we sparked lively discussions on shaping the future of global health through new medicines.

イノベーションは対話から。 TropIQ Health SciencesのKoen Dechering博士、Walter Bronkhorst博士がエーザイ筑波研究所に来訪されました。TropIQ は昆虫が媒介する感染症の撲滅をめざし、創薬研究や技術基盤の提供を行うオランダの企業です。 現在エーザイとは抗マラリア薬の共同研究を進めており、グローバルヘルスの未来を切り拓く新薬の開発について、活発なディスカッションが繰り広げられました。